ProPhase Labs Stockholders Deliver Strong Mandate at Special Meeting UNIONDALE, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, today announced that stockholders delivered a strong mandate at the Company’s September 9, 2025 Special Meeting, approving all proposals on the agenda. With each proposal receiving more than 75% support, ProPhase received clear authorization to move forward wi ...

Core Insights - Kenvue reported $3.84 billion in revenue for the quarter ended June 2025, reflecting a year-over-year decline of 4% and an EPS of $0.29 compared to $0.32 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $3.86 billion by 0.51%, while the EPS exceeded the consensus estimate of $0.28 by 3.57% [1] Financial Performance Metrics - Kenvue's net sales in the Self Care segment were $1.56 billion, slightly below the average estimate of $1.6 billion, marking a year-over-year decline of 4.9% [4] - In the Essential Health segment, net sales were $1.23 billion, matching the average estimate, but reflecting a year-over-year decrease of 2.9% [4] - The Skin Health and Beauty segment reported net sales of $1.06 billion, surpassing the average estimate of $1.04 billion, with a year-over-year decline of 4% [4] Stock Performance - Kenvue shares have returned +3.3% over the past month, outperforming the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Financial Data and Key Metrics Changes - The company reported a 4.2% decline in organic sales for Q2, which was below expectations, despite global consumption growing year over year [25][34] - Adjusted operating margin contracted by 10 basis points to 22.7%, with adjusted diluted EPS at $0.29 compared to $0.32 in the previous year [35][45] - Adjusted net income for Q2 was $560 million, reflecting an 8.3% decline year over year [45] Business Line Data and Key Metrics Changes - The Self Care business experienced a 5.9% decline in organic sales, primarily due to lower volumes and unfavorable seasonal dynamics [37] - Skin Health and Beauty saw a 3.7% decrease in organic sales, with consumption trends stabilizing globally for the first time in over a year [39][40] - Essential Health reported a 2.4% decline in organic sales, with challenges in the mouthwash business despite gaining share online [42][43] Market Data and Key Metrics Changes - In the U.S., 83% of the business held or gained market share, with notable performance in allergy products like Zyrtec [25][38] - Consumption trends improved sequentially in EMEA and Latin America, while North America and Asia Pacific faced challenges [40][72] - The allergy category in the U.S. recorded the second lowest incidences on record, impacting sales negatively [37] Company Strategy and Development Direction - The company is focusing on reducing complexity by streamlining its brand portfolio and prioritizing key markets and products [21][22] - A strategic review committee has been established to explore various alternatives for optimizing the brand portfolio [12] - The leadership aims to enhance operational efficiency and improve execution across major brands and markets [24][48] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the need for a consumer-centric approach and emphasized the importance of household penetration to drive market share [15][16] - The company revised its guidance for 2025, expecting organic sales to decline in low single digits due to current performance and market dynamics [46] - Management expressed confidence in the potential for turnaround, citing strong brand equity and a robust innovation pipeline [30][70] Other Important Information - The company has appointed new leaders to enhance capabilities in marketing, sales, digital, and AI [20][85] - A focus on flawless execution and faster decision-making is emphasized as critical to achieving growth [51][88] Q&A Session Summary Question: Discussion on complexity and focus on major brands - Management agreed on the need to focus on major brands and markets, acknowledging the complexity created within the organization [56][57] Question: Surprises upon stepping into the role and areas of excitement - Management noted surprise at the self-induced complexity and expressed excitement about the potential in EMEA and Latin America [68][72] Question: Framework for unlocking value and addressing low profitability segments - Management confirmed that strategic alternatives and operational excellence efforts are aligned, focusing on consumer understanding and demand creation [78][80] Question: Measuring success in restructuring efforts - Management stated that success will be measured by consumer purchasing behavior and sequential improvement in market share [84][88]

Financial Performance - Net sales reached $1056 million, a decrease of 0.9% year-over-year[16] - Organic net sales experienced a slight decrease of 0.1% year-over-year[16] - Adjusted gross profit was $403 million, down 6.9% year-over-year[16] - Adjusted gross margin was 38.1%, a decrease of 250 basis points[16] - Adjusted operating income was $1352 million, down 2.9% year-over-year[16] - Adjusted EPS increased by 7.5% to $057[16] Segment Performance - Consumer Self-Care Americas (CSCA) net sales decreased by 1.9% year-over-year to $622 million[43] - Consumer Self-Care International (CSCI) net sales increased by 0.7% year-over-year to $4343 million[43] - Perrigo OTC brands grew by 3.6%, while Perrigo OTC store brands decreased by 3.2%[19] Strategic Initiatives - Infant formula net sales increased by 9% year-over-year[14] - Store brand and contract infant formula net sales increased by 32% year-over-year[26] - Project Energize is expected to deliver $159 million in annual run rate gross savings[30] - Supply Chain Reinvention is expected to generate total benefits between $150-$200 million by the end of 2025[30] - The sale of the Dermacosmetics business is expected to close in Q1 2026, with proceeds prioritized for accelerating net leverage goals[30, 52]

Financial Data and Key Metrics Changes - The company reported a gross margin improvement of 160 basis points, contributing to strong cash flow and organic profit growth [7][19] - A&P (Advertising and Promotion) spending increased by 6.8% to 20.8% in the first half of the year, reflecting a strategic focus on growth drivers [19][21] - The company expects high single-digit operating profit growth for the year, driven by gross margin opportunities [55][78] Business Line Data and Key Metrics Changes - North America experienced a nearly 2% organic sales growth decline, attributed to a challenging consumer environment and inventory pressures [4][8] - Strong growth and market share gains were noted in oral health and digestive health brands, while pain relief and VMS (Vitamins, Minerals, and Supplements) showed mixed performance [11][12] - Centrum faced challenges in the U.S. market, with declines despite strong growth outside the U.S. [13][14] Market Data and Key Metrics Changes - EMEA, Latin America, and APAC markets performed well, with organic sales growth within the medium-term guidance of 4% to 6% [4][8] - Volume growth in EMEALATAM accelerated from 0.5% in Q1 to 1.6% in Q2, while Asia Pacific saw an increase from 3.3% to 3.9% [47][50] - The U.S. market showed a decline in volume, down 1.8% in Q2, impacting overall performance [48][49] Company Strategy and Development Direction - The company remains committed to its medium-term guidance of 4% to 6% growth, despite current challenges in the U.S. market [45][50] - Strategic investments are focused on supply chain productivity, innovation, and expanding access to lower-income consumers [18][39] - The company plans to continue its innovation-led premiumization strategy while addressing core business challenges [40][55] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging consumer environment in North America, with expectations of continued inventory pressures [8][16] - The company is optimistic about returning to growth in 2026, supported by new leadership and strategic initiatives [49][50] - Management expressed confidence in the resilience of the European market, particularly in oral health [52][53] Other Important Information - The nicotine replacement therapy business is a significant but challenging category, with a complex ownership structure impacting innovation [73][75] - The company is actively managing inventory levels with retailers to navigate the current economic environment [15][28] Q&A Session Summary Question: North America's performance and future growth expectations - Management noted that North America faced a nearly 2% decline in organic sales growth due to a challenging consumer environment and inventory pressures, with expectations for gradual recovery [4][8][16] Question: A&P spending and areas of reinvestment - A&P spending increased significantly, with a focus on driving growth through innovation and reaching lower-income consumers [19][21] Question: Share performance and competitive pressures - The decline in the percentage of business gaining or maintaining share was attributed to challenges with key brands like Advil and Centrum, with plans in place to stabilize performance [30][32] Question: Retailer environment and channel dynamics - Management discussed the impact of retailer destocking and channel shifts, particularly in the U.S. market, and emphasized the need to adapt to these changes [28][86] Question: Outlook for specific product categories - Management provided insights on the performance of Advil, Smoker's Health, and Centrum, highlighting ongoing challenges and upcoming innovations [60][66][68]

Financial Data and Key Metrics Changes - The company reported a decline in organic sales growth in North America of nearly 2% in Q2, contrasting with growth in EMEA, LatAm, and APAC, which were within the medium-term guidance of 4% to 6% [3][5][14] - Gross margin improved by 160 basis points, contributing to strong cash flow and organic profit growth [5][15] - A&P (Advertising and Promotion) spending increased by 6.8% to 20.8% in the first half of the year, reflecting a focus on growth drivers [16][19] Business Line Data and Key Metrics Changes - In North America, consumption grew slightly ahead of the market, with a 0.5% increase compared to a market decline of 0.5% [9][10] - Oral health and digestive health brands showed strong growth, with market share gains in brands like Tons and Benefiber [9][10] - Centrum experienced mid-single-digit growth outside the US but saw declines in the US, while Emergency brand continued to perform well [11][12] Market Data and Key Metrics Changes - The US market is facing challenges with low consumer confidence and inventory pressures, impacting overall performance [6][8][14] - EMEA and APAC regions showed positive trends, with volume growth accelerating in Q2 [47][51] - Central Europe reported high single-digit growth, while Western Europe experienced mid-single-digit growth, driven by strong performance in oral health [53][54] Company Strategy and Development Direction - The company remains committed to its medium-term guidance of 4% to 6% organic sales growth despite current challenges in the US market [49][56] - Focus on innovation and premiumization, particularly in key markets like India and Brazil, is part of the strategic plan [39][40] - The company aims to close the incidence treatment gap and expand reach to lower-income consumers while maintaining investment in A&P and R&D [16][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging consumer environment in the US, with expectations of continued inventory pressure and no significant improvement anticipated in the near term [14][22] - Confidence in the medium-term outlook remains strong, with expectations for improved performance in 2026 [49][56] - The company is actively managing its portfolio and focusing on driving market growth despite external challenges [36][41] Other Important Information - The nicotine replacement therapy (NRT) business is a significant part of the portfolio, with a complex ownership structure affecting innovation and growth [73][75] - The company expects a high single-digit growth in operating profit, supported by gross margin improvements and effective cost control [77][78] Q&A Session Summary Question: North America's performance and future growth expectations - Management noted that North America faced challenges due to a difficult consumer environment and inventory pressures, with expectations for a gradual return to growth [3][22][25] Question: A&P spending and areas of reinvestment - A&P spending increased significantly, with a focus on driving growth in key markets and improving ROI [16][19] Question: Share performance and competitive pressures - The decline in the percentage of business gaining or maintaining share was attributed to challenges with brands like Advil and Centrum, with plans in place to stabilize performance [28][30] Question: Impact of nicotine replacement therapy on growth - The NRT business had a significant impact on overall growth, with expectations for less decline in the second half of the year [76][80] Question: Channel shifts and inventory management - Management discussed the impact of channel shifts, particularly towards e-commerce, and the need for effective inventory management across channels [86][90]

The stock market has historically been a highly effective tool for compounding wealth over time. Another way to use the stock market to achieve your financial goals is to generate income from dividend stocks. Sometimes, it can make sense to target a stodgy company with a high yield, rather than allocate all your savings into high-octane growth stocks. Maybe you're simply looking to diversify, or maybe you're focused on generating a specific amount of dividends to help supplement income in retirement. In tha ...

On July 11, 2025, Andrew Hill Investment Advisors, Inc. disclosed it sold out its entire Johnson & Johnson (JNJ -0.60%) position, totaling $6.31 million in trades.What happenedAccording to a July 10, 2025 SEC filing, the firm exited its entire position in Johnson & Johnson during Q2 2025, selling all 38,037 shares for $6,308,131 in reported transaction value. Andrew Hill Investment Advisors no longer holds JNJ shares as of June 30, 2025, based on 13F disclosures.What else to knowThe sale represents a full e ...

Core Insights - Johnson & Johnson (NYSE: JNJ) is expected to report earnings of $2.68 per share and sales of $22.86 billion on July 16, 2025, compared to $2.82 per share and $22.45 billion in the same quarter last year [3] - The company has a market capitalization of $378 billion and reported $89 billion in revenue over the past twelve months, with $22 billion in operating profits and $22 billion in net income [4] Historical Performance - Historically, JNJ has delivered positive one-day returns in 55% of cases following earnings announcements over the past five years, with a median positive return of 2.3% and a peak one-day positive return of 6.1% [2][7] - Over the last five years, there have been 20 recorded earnings data points, with 11 resulting in positive and 9 in negative one-day returns [7] - The percentage of positive one-day returns drops to 33% when analyzing data from the last three years [7] Trading Strategies - Traders may consider taking a position prior to the earnings release based on historical data or wait for the earnings to be disclosed to analyze immediate and medium-term returns [6] - A correlation analysis between short-term and medium-term returns can guide trading choices, particularly if 1D and 5D returns demonstrate a strong correlation [8]

Group 1 - Haleon has appointed Carl Haney as Chief Research & Development Officer, effective August 1, 2025, following Franck Riot's departure after six years [1][2] - Carl Haney brings 13 years of experience from Estée Lauder and over 20 years from Procter & Gamble, focusing on innovation and R&D in consumer businesses [1][2] - The CEO of Haleon, Brian McNamara, expressed confidence in Haney's ability to drive transformative innovation and contribute to the company's new "Win as One" strategy [2][3] Group 2 - Franck Riot's contributions to Haleon were acknowledged, particularly in advancing the innovation agenda during the company's transition [3] - Carl Haney expressed enthusiasm about joining Haleon at a pivotal time, emphasizing the importance of R&D in achieving the company's goals of enhancing everyday health [3] - Haleon is positioned as a global leader in consumer health, with a diverse product portfolio across six major categories, including Oral Health and Pain Relief [4]